May 29, 2020 • ASCO Trial-in-Progress Poster – Phase 2 Study of MILs™ – NSCLC for the Treatment of Patients with NSCLC

WindMIL Therapeutics is proud to highlight a Trial-in-Progress (TiP) poster being presented at the American Society for Clinical Oncology (ASCO) 2020 virtual meeting. The poster summarizes WindMIL Therapeutic’s Phase 2 study of MILs™ – NSCLC for the treatment of patients with NSCLC.

May 28, 2020 • WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ – NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer

WindMIL Therapeutics today announced that the first patient has been dosed in the combination therapy portion of its Phase 2 clinical trial to assess the safety and efficacy of MILs™ – NSCLC in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who are refractory to, or have relapsed on, an anti-PD-1-containing […]

May 27, 2020 • WindMIL Therapeutics to Present at Jefferies Virtual Healthcare Conference 2020

WindMIL Therapeutics today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 8:00 am EDT.

May 19, 2020 • Company Update Presentation – 2020 UBS Virtual Global Healthcare Conference (Link to archived Webcast)

WindMIL Therapeutic’s Chairman and CEO Don Hayden presented a company update at the 2020 UBS Virtual Global Healthcare Conference on Monday, 18 May 2020.  Recordings of the webcast are available through 17 June 2020 at this link.

May 12, 2020 • WindMIL Therapeutics to Present at UBS Virtual Global Healthcare Conference

WindMIL Therapeutics today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 3:50 pm EDT.  

April 21, 2020 • WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

WindMIL Therapeutics announced it has begun enrollment in the combination therapy portion of its open-label, multi-center Phase 2a clinical trial to assess the safety and efficacy of MILs in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who are refractory to, or have relapsed on, an anti-PD-1-containing regimen. In this part […]

March 16, 2020 • BioProcess Insider: Grist for the MIL: CDMO Cognate making cell therapies for WindMIL

WindMIL Therapeutics has upped a contract with Cognate BioServices to make its marrow-infiltrating lymphocyte (MIL) cell therapies

March 10, 2020 • WindMIL Therapeutics and Cognate BioServices Announce Agreement to Expand MILs Manufacturing Capacity

WindMIL Therapeutics and Cognate BioServices, Inc. today announced they have entered an agreement to expand WindMIL’s clinical manufacturing capacity.

March 5, 2020 • WindMIL Therapeutics Appoints Patrick Fabbio as Chief Financial Officer

WindMIL Therapeutics today announced the appointment of Patrick Fabbio as Chief Financial Officer, effective March 30. Mr. Fabbio brings more than 25 years of financial, operational and transactional leadership experience in both publicly traded and privately held life science and pharmaceutical companies to this role. He will lead development and execution of the company’s financial […]

February 26, 2020 • BioCentury Emerging Company Profile – WindMIL: T cell source is key

(article behind paywall)